RECURRENT MELANOMA

This study is testing a drug called tipifarnib in children and young adults whose advanced cancers have a specific genetic change in a gene called HRAS. The goal is to see if the drug can shrink tumors and control the disease. Participants take the drug as a pill or through a fee…

This study is testing an experimental drug called dinaciclib in people with stage IV melanoma that has spread. The main goal is to see if the treatment helps patients live at least one year longer. Researchers will also monitor how well it controls the cancer's growth and what si…

This study tested whether adding a drug called GM-CSF (sargramostim) to an existing immune-boosting cancer drug (ipilimumab) could help patients with advanced melanoma live longer. The trial involved 245 adults whose melanoma could not be removed by surgery. Researchers compared …

This study is for people with advanced melanoma that has a specific BRAF gene mutation and cannot be removed by surgery. It is testing which order of two powerful treatment combinations leads to longer survival. One group starts with immunotherapy (ipilimumab + nivolumab) and swi…

This large study aimed to find the best treatment to prevent melanoma skin cancer from returning after it has been surgically removed. It compared a newer immune-boosting drug called ipilimumab against the standard treatment, interferon. Over 1,600 patients with high-risk melanom…

This early-stage study is testing the safety and best dose of two drugs, riluzole and sorafenib, when given together. It's for people with advanced solid tumors or melanoma that have spread and are no longer responding to standard treatments. The goal is to see if this combinatio…

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This study tested whether adding high-dose interferon to the immunotherapy drug ipilimumab helps control advanced melanoma better than ipilimumab alone. It also compared two different doses of ipilimumab. The trial involved 88 adults with stage III or IV melanoma that couldn't be…

This early-stage study is testing a new combination of two existing cancer drugs, pembrolizumab and ziv-aflibercept, in patients with advanced solid tumors. The main goal is to find the safest and most effective dose of the combination. Researchers will also look for early signs …

This large national trial is testing whether choosing cancer drugs based on the specific genetic changes found in a patient's tumor is more effective than standard approaches. It is for adults with advanced solid tumors, lymphoma, or multiple myeloma that have progressed after at…

This study is testing whether a two-part immunotherapy can help patients with advanced melanoma whose cancer has continued to grow despite standard immune-based treatments. It combines a modified virus injected directly into tumors (T-VEC) with an intravenous drug (pembrolizumab)…